“…Of these, 83 articles were excluded because of few numbers of patients (<50 patients) and lack of comparison group ( Fig. 1 ), leaving four studies for the analysis [ 31 , [33] , [34] , [35] ]. Fig.…”
Section: Resultsmentioning
confidence: 99%
“…The KROG 16-16 study attempted to investigate the potential subgroups (as cN2 and cT3-4) that would benefit ENI, in ypN0 as after PST and breast-conserving surgery [ 31 ]. Seventy-three patients were cN2, of these 41 (40.1%) received ENI while 32 patients (20.1%) did not.…”
Section: Resultsmentioning
confidence: 99%
“…2 . Thus, ultimately, seven articles were included in the meta-analysis [ 31 , [37] , [38] , [39] , [40] , [41] , [42] ] and all studies were retrospective. Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Although pCR has been associated with improved survival, the association is stronger in triple-negative and HER2+ hormone receptor (HR)-negative patients who received an anti-HER2 therapy [ 28 , 29 ]. Therefore, recommendations for loco-regional RT in specific subtypes could result in overtreatment [ 30 , 31 ].…”
“…Of these, 83 articles were excluded because of few numbers of patients (<50 patients) and lack of comparison group ( Fig. 1 ), leaving four studies for the analysis [ 31 , [33] , [34] , [35] ]. Fig.…”
Section: Resultsmentioning
confidence: 99%
“…The KROG 16-16 study attempted to investigate the potential subgroups (as cN2 and cT3-4) that would benefit ENI, in ypN0 as after PST and breast-conserving surgery [ 31 ]. Seventy-three patients were cN2, of these 41 (40.1%) received ENI while 32 patients (20.1%) did not.…”
Section: Resultsmentioning
confidence: 99%
“…2 . Thus, ultimately, seven articles were included in the meta-analysis [ 31 , [37] , [38] , [39] , [40] , [41] , [42] ] and all studies were retrospective. Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Although pCR has been associated with improved survival, the association is stronger in triple-negative and HER2+ hormone receptor (HR)-negative patients who received an anti-HER2 therapy [ 28 , 29 ]. Therefore, recommendations for loco-regional RT in specific subtypes could result in overtreatment [ 30 , 31 ].…”
“…Although RT has been accepted as one of the most significant treatments for breast cancer patients, the impact of molecular subtypes on RT response in early‐stage breast cancer patients has not been exactly elucidated in previous literatures . To the best of our knowledge, this is the first population‐based retrospective study aimed to address the prognostic role of RT and its impact on OS and BCSS in young early‐stage breast cancer female patients according to molecular subtypes.…”
Background
To evaluate the significance and benefit of radiotherapy (RT) in young early‐stage breast cancer patients according to different molecular subtypes.
Methods
We conducted a retrospective cohort study utilizing the Surveillance, Epidemiology, and End Results database with known hormone receptor (HoR) and human epidermal growth factor receptor 2 (HER2) status. Female patients aged 18‐45, received RT treatment, and diagnosed with stage T1‐3, N0‐3, M0 primary breast cancer between 2010 and 2013 were identified.
Results
Of all the 23 148 included patients, 14 708 (63.54%), 3385 (14.62%), 1225 (5.29%), and 3830 (16.55%) were diagnosed with luminal‐A (HoR + HER2‐), luminal‐B (HoR + HER2+), HER2‐enriched (HoR‐HER2+), and triple‐negative (HoR‐HER2‐) breast cancer, respectively. RT was significantly correlated with improved overall survival (OS, HR: 0.295; 95% CI:0.138‐0.63, P = 0.002) and breast cancer‐specific survival (BCSS, HR: 0.328; 95% CI: 0.153‐0.702, P = 0.004) in HER2‐enriched patients. In addition, a significantly prolonged OS was also observed when RT was given to luminal‐A (HR: 0.696; 95% CI: 0.538‐0.902, P = 0.006) and luminal‐B (HR: 0.385; 95% CI:0.199‐0.744, P = 0.005) breast cancer patients compared to those without RT. Multivariable‐adjusted analyses showed that HER2 was a significant favorable factor for RT benefit in breast cancer patients.
Conclusions
RT could offer significant survival benefit in luminal‐A, luminal‐B, and especially HER2‐enriched young early‐stage breast cancer female patients. The results enabled clinicians to predict the benefits of RT and improve evidence‐based treatment for breast cancer patients.
Is elective nodal irradiation beneficial in patients with pathologically negative lymph nodes after neoadjuvant chemotherapy and breast-conserving surgery for clinical stage II-III breast cancer? a multicentre retrospective study .
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
